ClinicalTrials.gg

Program

icalcaprant

Also written as “Icalcaprant”, “CVL-354” and “ABBV-1354”.

In AbbVie's pipeline, KOR antagonist. Its studies are mostly in Bipolar Disorder · Depressive Disorder, Major, led by AbbVie.

Furthest: phase 2, since Nov 18, 20246 company-led studies, 2 open or runningNext primary completion: Sep 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AbbVie62 open or runningphase 2since Nov 18, 2024Nov 17, 2021Sep 2027phase 2 · NCT07276997
  • Named in AbbVie’s own pipeline as Icalcaprant (ABBV-1354), phase 2, as of Jul 30, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 17, 2021First study: phase 1 study in Healthy ParticipantsFirst studyNCT05138653 · 73 enrolled · United States
  2. Nov 18, 2024Phase 2 study in Bipolar DisorderNCT06696755 · 195 planned · United States
  3. Dec 4, 20242 phase 1 studies in Healthy VolunteerNCT06722430, NCT06722417
  4. Oct 17, 2025Phase 1 study in Healthy VolunteerNCT07219017 · 8 enrolled · United States
  5. Dec 2, 2025Phase 2 study in Depressive Disorder, MajorNCT07276997 · 195 planned · United States

Ahead

  1. Sep 2027Primary completion: phase 2 study in Depressive Disorder, MajorNCT07276997
  2. Nov 2027Primary completion: phase 2 study in Bipolar DisorderNCT06696755

TargetBeta

“KOR antagonist”the company's pipeline, read by Claude · source

Other programs on OPRK1

ProgramCompanyFurthest phaseStudies
Naltrexoneruleorexigen-therapeutics-incphase 442
nalmefeneruleH. Lundbeckphase 420
NalbuphineruleTrevi Therapeuticsphase 420
cebranopadolruleTris Pharmaphase 318
AticaprantruleJohnson & Johnsonphase 313
nalfurafineruletoray-industries-incphase 39
asimadolineruletioga-pharmaceuticalsphase 36

Studies

All 6 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07276997Depressive Disorder, Major · United States2RecruitingSep 2027195
NCT07219017Healthy Volunteer · United States1CompletedDec 9, 20258
NCT06722430Healthy Volunteer · United States1CompletedJan 13, 202512
NCT06722417Healthy Volunteer · United States1CompletedJan 17, 202516
NCT06696755Bipolar Disorder · United States2RecruitingNov 2027195
NCT05138653Healthy Participants · United States1CompletedJan 23, 202373

How it is read

Names in the registry

  • “Icalcaprant”, 4 entries
  • “CVL-354”, 2 entries
  • “ABBV-1354”, 1 entry

Codes read as this program: ABBV1354.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.